Hyperinsulinemic euglycemic clamp technique has been widely used as a gold standard for quantifying insulin resistance in vivo. It measures the amount of glucose infused intravenously required for the prevention of hypoglycemia resulted from increased levels of plasma insulin. This technique is rarely performed in clinical care, but is used in medical research to assess the effects of various physiological perturbations such as dietary, exercise and drug interventions. Intravenous infusion of lipids is often used together with a traditional hyperinsulinemic clamp technique in order to investigate the effect of lipid induced insulin resistance. The basic protocol takes about 2 hours while one with intralipid infusion takes more than 5 hours. Following the continuous intravenous infusion of insulin, the levels of plasma glucose is maintained by varying the rate of glucose infusion, which is determined by checking the blood glucose levels every 5 minutes. The rate of glucose infusion during the last 30 minutes of the test (i.e., steady state) determines patient¡¯s insulin sensitivity. If high levels (7.5 mg/min or higher) are required, the patient is insulin-sensitive. Very low levels (4.0 mg/min or lower) indicate that the body is resistant to insulin action. Levels between 4.0 and 7.5 mg/min are not definitive and suggest "impaired glucose tolerance," an early sign of insulin resistance.

Even though it is a precise technique to quantify the insulin sensitivity of peripheral tissues, it suffers from the laborious effort to carry out this experiment preventing its wider use in clinical research. Since it requires knowing a blood glucose level every 5 minutes, the experiment can go wrong due to any factors hindering a blood draw such as clotting. This problem can be overcome by using a continuous glucose monitoring system, which can measure the dynamic changes in the subcutaneous glucose levels without a blood draw. As an alternative to the laborious conventional glucose clamp technique, we can provide an efficient solution by developing an automated feed-back control system using Labview¢ç, which is composed of three subsystems; 1) Data acquisition from a continuous glucose monitoring system; 2) Controller to compute the rate of glucose infusion required for the prevention of hypoglycemia; 3) Actuator to change the flow rate setting in the infusion pumps. Our integrated solution will be able to allow this glucose clamp technique to be used by more researchers with ease.